ATP-FFR与尼可地尔-FFR指导疑似心绞痛患者长期结局比较
本单中心前瞻性注册研究纳入363例疑似心绞痛患者(543支血管),比较ATP-FFR与冠脉内尼可地尔-FFR指导治疗策略的长期结局。FFR≤0.80定义为缺血组,FFR>0.80为非缺血组,平均随访6.4±3.1年。结果显示两种充血药物在各亚组的ACS、CCS及靶血管血运重建方面均无统计学显著差异。
要点
- 冠脉内尼可地尔2mg可作为FFR测量的替代充血药物。
- 缺血组与非缺血组中两种药物指导的长期ACS和CCS发生率均无显著差异。
- 尼可地尔-FFR指导策略在真实世界临床实践中安全有效。
核心结论
- 冠脉内尼可地尔可安全有效地作为FFR测量的替代充血药物。
- 尼可地尔-FFR指导的长期血管相关结局与ATP-FFR相比无统计学显著差异。
研究设计与样本
- 单中心前瞻性注册研究,纳入2012年4月至2017年12月连续363例患者(543支血管)。
- FFR测量使用静脉ATP输注(150µg/kg/min)和/或冠脉内尼可地尔(2mg推注)。
- 平均随访时间为6.4±3.1年。
主要发现
- 363例患者中123例(33.9%)接受PCI,5例(1.4%)接受CABG。
- 总体靶血管血运重建发生率为3.0%(按血管计算)。
- 缺血组中ATP-FFR的ACS发生率为0.0%,尼可地尔-FFR为0.4%(log-rank p=0.328)。
- 缺血组中ATP-FFR的CCS发生率为15.9%,尼可地尔-FFR为16.4%(p=0.059)。
- 非缺血组中ATP-FFR的ACS发生率为0.7%,尼可地尔-FFR为0.3%(p=0.521)。
关键数值与推荐
- FFR≤0.80定义为缺血组,FFR>0.80定义为非缺血组。
- ATP给药方案为静脉输注150µg/kg/min。
- 尼可地尔给药方案为冠脉内2mg推注。
临床怎么用
- 对于无法使用或不宜使用ATP的患者,可考虑冠脉内尼可地尔作为FFR测量的替代充血药物。
- 尼可地尔-FFR指导的血运重建决策在长期临床结局方面与ATP-FFR相当。
局限性
- 本研究为单中心注册研究,可能存在选择偏倚。
- 两种充血药物的FFR测量并非完全随机分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Fractional flow reserve (FFR)-guided revascularization improves long-term outcomes in patients with coronary artery disease. Although adenosine triphosphate (ATP) is the standard hyperemic agent, nicorandil (NIC) has emerged as a practical alternative due to its combined nitrate-like and ATP-sensitive potassium channel–activating properties. However, data on long-term vessel-related outcomes guided by NIC-induced FFR are limited. Aims To compare long-term clinical and vessel-based outcomes in patients with suspected angina pectoris whose treatment strategies were guided by ATP-induced FFR (ATP-FFR) versus intracoronary nicorandil-induced FFR (NIC-FFR). Methods This single-center, prospective registry enrolled 363 consecutive patients (543 vessels) who underwent FFR measurement between April 2012 and December 2017. FFR was assessed using intravenous ATP infusion (150 µg/kg/min) and/or intracoronary NIC (2 mg bolus). Ischemic and non-ischemic groups were defined as FFR ≤ 0.80 and > 0.80, respectively. Long-term clinical events were evaluated over a mean follow-up of 6.4 ± 3.1 years. Results Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) were performed in 123 (33.9%) and 5 (1.4%) patients, respectively. Overall, target vessel revascularization occurred in 3.0% of vessels. In the ischemic groups (FFR ≤ 0.80), the incidence of acute coronary syndrome (ACS) was 0.0% for ATP-FFR and 0.4% for NIC-FFR (log-rank p = 0.328), and chronic coronary syndrome (CCS) occurred in 15.9% and 16.4%, respectively (p = 0.059). Among non-ischemic vessels (FFR > 0.80), ACS occurred in 0.7% versus 0.3% (p = 0.521) and CCS in 7.6% versus 5.8% (p = 0.374). Kaplan–Meier analyses showed no significant differences between the two hyperemic agents across all subgroups. Conclusions Intracoronary NIC can be safely and effectively used as an alternative hyperemic agent for FFR measurement. Long-term vessel-related outcomes guided by NIC-FFR showed no statistically significant differences compared with those guided by ATP-FFR, supporting its applicability in real-world practice.
引用
- Catheterization and Cardiovascular Interventions:Long‐Term Outcomes of Patients With Suspected Angina Pectoris Following Clinical Decision‐Making Guided by ATP‐FFR Versus Nicorandil‐FFR
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。